Prospective Evaluation of Outcomes of Everolimus-Eluting Stent (XIENCE V) Implantation for Unprotected Left Main Coronary Artery Stenosis: Multicenter Trial.

Trial Profile

Prospective Evaluation of Outcomes of Everolimus-Eluting Stent (XIENCE V) Implantation for Unprotected Left Main Coronary Artery Stenosis: Multicenter Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Everolimus; Sirolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms PRE-COMBAT-2
  • Most Recent Events

    • 19 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Aug 2012 Drug company (Abbott Laboratories) added as reported by ClinicalTrials.gov.
    • 03 Jun 2011 Actual initiation date changed from May 2009 to Aug 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top